RSSDI Collaborates with Wellthy Therapeutics to Provide Digital Diabetes Care

Asia’s largest diabetes organization, RSSDI collaborates with Wellthy Therapeutics to launch South Asia’s first clinical trial for diabetes on November 16, 2017.

The Digital Diabetes Therapy brought by Wellthy Therapeutics is all set to prove the efficacy of its 16-week structured diabetes management program, which is delivered through a mobile app. Research Society for the Study of Diabetes India (RSSDI) is actively involved in diabetes awareness programs. Wellthy Therapeutics is a digital therapeutics company that uses artificial intelligence (AI) and patient centric design for treatment of diabetic patients.

Wellthy Therapeutics has commercialized a digital therapy for type 2 diabetes patients that is the first endorsed digital diabetes intervention by Asia’s largest Diabetes Association (RSSDI). The trial was launched by Past President of RSSDI, Dr. Sarita Bajaj at the RSSDI Annual Conference in Bhubaneswar, India. The result of this multi-center randomized control trial will be measured by the HbA1C levels of patients before and after the trial.

Mr. Abhishek Shah, Co-founder and CEO of Wellthy Therapeutics said, “Wellthy app has already demonstrated its efficacy in various pilot studies, this formal clinical trial conducted with the RSSDI will provide the evidence necessary to show that digital therapeutics have the potential to improve the lives of diabetes patients in India and around the world.”

It is common for diabetic patients to make an error in diabetes management by either overeating carbohydrates, not exercising enough or forgetting to take medicine. According to the data of International Diabetes Federation, an estimated 69.1 million people in India are living with diabetes and around 77.2 million are diagnosed with pre-diabetes, which are at high-risk for diabetes and cardio-vascular disease. As a part of the program, personalized diabetes self-management education and real time coaching will be offered through dedicated health coaches and an artificial intelligence powered chat bot, to engage and improve the health of patients with type 2 diabetes.

Dr. Rajeev Chawla, Current President Elect of RSSDI said, “This clinical trial holds tremendous potential in terms of changing outcomes for people living with diabetes by making it easier for them to manage their blood sugar levels and improving their overall quality of life.”

You may be interested

Business

Tricks Used by Insurance Companies to Deny Legit Claims

media - December 10, 2018

Health insurance companies strategize in making more and more money by paying out as little as possible. Many times, they deny legitimate claims which are covered under…

New Study Suggests Typical Use of Sunscreens Offers Less Sun Protection
Business
Business

New Study Suggests Typical Use of Sunscreens Offers Less Sun Protection

Mohit Joshi - December 10, 2018

Researchers from King's College London revealed that use of sunscreen offers less than half the sun protection as users apply more thinly than manufacturers recommend. In a…

Tamoxifen Market: Segmented by Application and Geography Trends, Growth and Forecasts 2026
Healthcare
Healthcare

Tamoxifen Market: Segmented by Application and Geography Trends, Growth and Forecasts 2026

Albert R - December 10, 2018

Tamoxifen Market report is a research database spread across various pages with multiple tables and figures in it. The research covers a valuable source of perceptive information…

Most from this category